Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ALE.F02

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: ALE.F02

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Morningside Venture

            Deal Size: $67.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing June 15, 2021

            Details:

            Alentis’ lead molecules ALE.F02 and ALE.C04 are highly selective anti-Claudin-1 mAb that recognize pathological overexpressed and conformation-dependent Claudin-1 epitopes in fibrotic disease and cancer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BOS-580

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: BOS-580

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Boston Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement September 01, 2020

            Details:

            Under the terms of the agreement, Boston Pharmaceuticals will license worldwide development and commercial rights to the drug candidate BOS-580, for the treatment of Non-Alcoholic Steatohepatitis (NASH) from Novartis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CM5480

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CM5480

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: CalciMedica

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration July 21, 2020

            Details:

            CalciMedica to use EpiPharma’s state-of-the-art Pre-clinical Drug Testing and Diagnostics Laboratory Platform to accelerate the discovery and development of CalciMedica’s CRAC channel inhibitor novel drug pipeline.